Cerebrolysin in SAH (Subarachnoidal Haemorrhage) - Observational Study

SAH (Subarachnoid Hemorrhage) Clinical Trial

Official title:

Cerebrolysin in Patients Diagnosed With SAH - an Observational Cohort Study (PILOT)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06429943
• Other study ID #: SAH/2020/2023
• Status: Completed
• Start date: January 15, 2021
• Est. completion date: January 10, 2023

Study information

• Verified date: December 2023
• Source: Pomeranian Medical University Szczecin
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Subarachnoid haemorrhage often affects people in middle age and is associated with high mortality or neurological damage. In recent years, advances in surgical techniques have im-proved the mortality rate. However, there is still need for the research for the optimal possible final effect of treatment. In our study, we've decided to examine the effect of a multimodal approach including Cerebrolysin in the supportive treatment of patients. We've examined the supply of neuroprotective drugs and neuromonitoring.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 47
• Est. completion date: January 10, 2023
• Est. primary completion date: October 15, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• age >18 years old, diagnosis of SAH, treatment in ICU conditions

Exclusion Criteria:

• age <18 years, medical history of allergy to Cerebrolysin, acute renal failure, pregnancy, multi organ trauma, death within 48 hours after admission

Related Conditions & MeSH terms

• Hemorrhage
• SAH (Subarachnoid Hemorrhage)
• Subarachnoid Hemorrhage

Locations

Country	Name	City	State
Poland	Pomeranian Medical University, University Hospital no.1	Szczecin

Sponsors (1)

Lead Sponsor	Collaborator
Pomeranian Medical University Szczecin

Country where clinical trial is conducted

Poland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	GOS Glasgow Outcome Scale	Glasgow Outcome Scale - 5 points scale, characterizing the patients' deficits	1 month
Secondary	LOS Length of Stay	length of stay in days, that patient spent in hospital/ intensive care unit	hospitalisation time
Secondary	mortality	mortality	1 month